A NEW ORALLY-ACTIVE OXYTOCIN ANTAGONIST

被引：0
|
作者：
PETTIBONE, DJ
CLINESCHMIDT, BV
KISHEL, M
LIS, EV
REISS, DR
WOYDEN, CJ
BOCK, MG
CHIU, SHL
EVANS, BE
FREIDINGER, RM
HOBBS, DW
KAUFMAN, MJ
THOMPSON, KL
VEBER, DF
WILLIAMS, PD
COOK, MJ
HALUSKA, GJ
NOVY, MJ
LOWENSOHN, RI
机构：
[1] MERCK SHARP & DOHME LTD,RAHWAY,NJ 07065
[2] MERCK SHARP & DOHME LTD,W POINT,PA 19486
[3] OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006
[4] OREGON HLTH SCI UNIV,PORTLAND,OR 97201
来源：
FASEB JOURNAL | 1993年 / 7卷 / 03期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A478 / A478
页数：1
相关论文
共 50 条
  • [31] PROTECTION FROM PULMONARY-HYPERTENSION WITH AN ORALLY-ACTIVE ENDOTHELIN RECEPTOR ANTAGONIST IN HYPOXIC RATS
    EDDAHIBI, S
    RAFFESTIN, B
    CLOZEL, M
    LEVAME, M
    ADNOT, S
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1995, 268 (02): : H828 - H835
  • [32] PHARMACOLOGY OF AN ACTIVE METABOLITE OF DUP-753 - AN ORALLY-ACTIVE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST
    TIMMERMANS, PBMWM
    WONG, PC
    PRICE, WA
    CHIU, AT
    DUNCIA, JV
    CARINI, DJ
    WEXLER, RR
    JOHNSON, AL
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (03) : 699 - 699
  • [33] SELECTION OF AN ORALLY-ACTIVE GLYCOPROTEIN-IIB/IIIA RECEPTOR ANTAGONIST FOR CLINICAL-TRIALS
    ZABLOCKI, J
    NICHOLSON, N
    TAITE, B
    PANZERKNODLE, S
    SALYERS, A
    HAAS, N
    SZALONY, J
    FEIGEN, L
    HERIN, M
    JACQMIN, P
    LESNE, M
    BOVY, P
    TJOENG, FS
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1244 - 1244
  • [34] THE PHARMACOLOGY OF SCH-50911 - A NOVEL, ORALLY-ACTIVE GABA-B RECEPTOR ANTAGONIST
    BOLSER, DC
    BLYTHIN, DJ
    CHAPMAN, RW
    EGAN, RW
    HEY, JA
    RIZZO, C
    KUO, SC
    KREUTNER, W
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1995, 274 (03): : 1393 - 1398
  • [35] A NOVEL SERIES OF ORALLY-ACTIVE ANTIPLATELET AGENTS
    ZABLOCKI, JA
    TJOENG, FS
    BOVY, PR
    MIYANO, M
    GARLAND, RB
    WILLIAMS, K
    SCHRETZMAN, L
    ZUPEC, ME
    RICO, JG
    LINDMARK, RJ
    TOTH, MV
    MCMACKINS, DE
    ADAMS, SP
    PANZERKNODLE, SG
    NICHOLSON, NS
    TAITE, BB
    SALYERS, AK
    KING, LW
    CAMPION, JG
    FEIGEN, LP
    BIOORGANIC & MEDICINAL CHEMISTRY, 1995, 3 (05) : 539 - 551
  • [36] ORALLY-ACTIVE PT(IV) ANTITUMOR COMPLEXES
    GIANDOMENICO, CM
    ABRAMS, MJ
    MURRER, BA
    VOLLANO, JF
    HARRAP, KR
    KELLAND, LR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1994, 207 : 233 - INOR
  • [37] THE EFFECT ON PLATELETS OF A STABLE ORALLY-ACTIVE IMIDAZOQUINAZOLINE
    TAYLOR, R
    FLEMING, S
    ARNOLD, J
    JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 24 (8-9): : 423 - 424
  • [38] THIOXYLOSIDE DERIVATIVES AS ORALLY-ACTIVE VENOUS ANTITHROMBOTICS
    BELLAMY, F
    BARBEROUSSE, V
    MARTIN, N
    MASSON, P
    MILLET, J
    SAMRETH, S
    SEPULCHRE, C
    THEVENIAUX, J
    HORTON, D
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1995, 30 : S101 - S115
  • [39] VALSARTAN, A POTENT, ORALLY-ACTIVE ANGIOTENSIN-II ANTAGONIST DEVELOPED FROM THE STRUCTURALLY NEW AMINO-ACID SERIES
    BUHLMAYER, P
    FURET, P
    CRISCIONE, L
    DEGASPARO, M
    WHITEBREAD, S
    SCHMIDLIN, T
    LATTMANN, R
    WOOD, J
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (01) : 29 - 34
  • [40] RS-39604 - A POTENT, SELECTIVE AND ORALLY-ACTIVE 5-HT4 RECEPTOR ANTAGONIST
    HEGDE, SS
    BONHAUS, DW
    JOHNSON, LG
    LEUNG, E
    CLARK, RD
    EGLEN, RM
    BRITISH JOURNAL OF PHARMACOLOGY, 1995, 115 (06) : 1087 - 1095
12345